Research ExplorerPublicationsLong-term benefits of targeted micronutrition with the holoB...

Long-term benefits of targeted micronutrition with the holoBLG lozenge in house dust mite allergic patients

Standard

Long-term benefits of targeted micronutrition with the holoBLG lozenge in house dust mite allergic patients. / Bergmann, Karl-Christian; Raab, Jennifer; Krause, Linda; Becker, Sylvia; Kugler, Sebastian; Zuberbier, Torsten; Roth-Walter, Franziska; Jensen-Jarolim, Erika; Kramer, Matthias F.; Graessel, Anke.

In: Allergo J Int, Vol. 31, 13.01.2022, p. 161–171.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bergmann, K-C, Raab, J, Krause, L, Becker, S, Kugler, S, Zuberbier, T, Roth-Walter, F, Jensen-Jarolim, E, Kramer, MF & Graessel, A 2022, 'Long-term benefits of targeted micronutrition with the holoBLG lozenge in house dust mite allergic patients', Allergo J Int, vol. 31, pp. 161–171. https://doi.org/10.1007/s40629-021-00197-z

APA

Bergmann, K-C., Raab, J., Krause, L., Becker, S., Kugler, S., Zuberbier, T., Roth-Walter, F., Jensen-Jarolim, E., Kramer, M. F., & Graessel, A. (2022). Long-term benefits of targeted micronutrition with the holoBLG lozenge in house dust mite allergic patients. Allergo J Int, 31, 161–171. https://doi.org/10.1007/s40629-021-00197-z

Vancouver

Bergmann K-C, Raab J, Krause L, Becker S, Kugler S, Zuberbier T et al. Long-term benefits of targeted micronutrition with the holoBLG lozenge in house dust mite allergic patients. Allergo J Int. 2022 Jan 13;31:161–171. https://doi.org/10.1007/s40629-021-00197-z

Bibtex

@article{aee021f30bc24c91aa5b3fb96b0770d7,
title = "Long-term benefits of targeted micronutrition with the holoBLG lozenge in house dust mite allergic patients",
abstract = "PurposeThe long-term effects of targeted micronutrition with the holoBLG lozenge in house dust mite (HDM) allergic rhinoconjunctivitis (ARC) patients were evaluated at a follow-up visit in an allergen exposure chamber (AEC).MethodsPatients who were supplemented for 3‑months with the holoBLG lozenge in a previous study with two controlled HDM-AEC challenges [visits: V1, V3] were recruited for a third AEC challenge (V5) 7–8 months after cessation of supplementation. Symptoms (nose, conjunctival, bronchial, others), well-being, and lung function parameters were recorded exactly as in the previous study. Primary endpoint was change in median Total Nasal Symptom Score (TNSS) at V5 compared to V1. Secondary endpoints included e.g. change in median Total Symptom Score (TSS) and the exploratory analysis of temporal evolution of symptom scores using linear mixed effects models.ResultsOf the 32 patients included in the original study, 27 could be recruited for the follow-up visit with a third AEC challenge. An improvement of 20% (p = 0.15) in the primary endpoint TNSS [V1: 2.5 (interquartile range [IQR]: 1–4), V5: 2.0 (IQR: 1–3)] was observed; 40% (p = 0.04) improvement was seen for the TSS [V1: 5.0 (IQR: 3–9), V5: 3.0 (IQR: 2–5.5)]. Analysis of temporal evolution of all symptom scores, and the personal well-being revealed sustained, clinically meaningful improvement at V5 compared to V1. No relevant lung function parameter differences were observed.ConclusionsSustained long-term reduction of TNSS (primary endpoint) and sustained long-term improvement of secondary endpoints (temporal evolution of all symptom scores and well-being) were demonstrated 7–8 months after cessation of holoBLG supplementation, indicative of a long-lasting nature of immune resilience induced by holoBLG.Trial registrationThe study was registered at clinicaltrials.gov (NCT04872868).",
author = "Karl-Christian Bergmann and Jennifer Raab and Linda Krause and Sylvia Becker and Sebastian Kugler and Torsten Zuberbier and Franziska Roth-Walter and Erika Jensen-Jarolim and Kramer, {Matthias F.} and Anke Graessel",
year = "2022",
month = jan,
day = "13",
doi = "10.1007/s40629-021-00197-z",
language = "English",
volume = "31",
pages = "161–171",
journal = "Allergo J Int",
issn = "2197-0378",
publisher = "Springer Medizin",

}

RIS

TY - JOUR

T1 - Long-term benefits of targeted micronutrition with the holoBLG lozenge in house dust mite allergic patients

AU - Bergmann, Karl-Christian

AU - Raab, Jennifer

AU - Krause, Linda

AU - Becker, Sylvia

AU - Kugler, Sebastian

AU - Zuberbier, Torsten

AU - Roth-Walter, Franziska

AU - Jensen-Jarolim, Erika

AU - Kramer, Matthias F.

AU - Graessel, Anke

PY - 2022/1/13

Y1 - 2022/1/13

N2 - PurposeThe long-term effects of targeted micronutrition with the holoBLG lozenge in house dust mite (HDM) allergic rhinoconjunctivitis (ARC) patients were evaluated at a follow-up visit in an allergen exposure chamber (AEC).MethodsPatients who were supplemented for 3‑months with the holoBLG lozenge in a previous study with two controlled HDM-AEC challenges [visits: V1, V3] were recruited for a third AEC challenge (V5) 7–8 months after cessation of supplementation. Symptoms (nose, conjunctival, bronchial, others), well-being, and lung function parameters were recorded exactly as in the previous study. Primary endpoint was change in median Total Nasal Symptom Score (TNSS) at V5 compared to V1. Secondary endpoints included e.g. change in median Total Symptom Score (TSS) and the exploratory analysis of temporal evolution of symptom scores using linear mixed effects models.ResultsOf the 32 patients included in the original study, 27 could be recruited for the follow-up visit with a third AEC challenge. An improvement of 20% (p = 0.15) in the primary endpoint TNSS [V1: 2.5 (interquartile range [IQR]: 1–4), V5: 2.0 (IQR: 1–3)] was observed; 40% (p = 0.04) improvement was seen for the TSS [V1: 5.0 (IQR: 3–9), V5: 3.0 (IQR: 2–5.5)]. Analysis of temporal evolution of all symptom scores, and the personal well-being revealed sustained, clinically meaningful improvement at V5 compared to V1. No relevant lung function parameter differences were observed.ConclusionsSustained long-term reduction of TNSS (primary endpoint) and sustained long-term improvement of secondary endpoints (temporal evolution of all symptom scores and well-being) were demonstrated 7–8 months after cessation of holoBLG supplementation, indicative of a long-lasting nature of immune resilience induced by holoBLG.Trial registrationThe study was registered at clinicaltrials.gov (NCT04872868).

AB - PurposeThe long-term effects of targeted micronutrition with the holoBLG lozenge in house dust mite (HDM) allergic rhinoconjunctivitis (ARC) patients were evaluated at a follow-up visit in an allergen exposure chamber (AEC).MethodsPatients who were supplemented for 3‑months with the holoBLG lozenge in a previous study with two controlled HDM-AEC challenges [visits: V1, V3] were recruited for a third AEC challenge (V5) 7–8 months after cessation of supplementation. Symptoms (nose, conjunctival, bronchial, others), well-being, and lung function parameters were recorded exactly as in the previous study. Primary endpoint was change in median Total Nasal Symptom Score (TNSS) at V5 compared to V1. Secondary endpoints included e.g. change in median Total Symptom Score (TSS) and the exploratory analysis of temporal evolution of symptom scores using linear mixed effects models.ResultsOf the 32 patients included in the original study, 27 could be recruited for the follow-up visit with a third AEC challenge. An improvement of 20% (p = 0.15) in the primary endpoint TNSS [V1: 2.5 (interquartile range [IQR]: 1–4), V5: 2.0 (IQR: 1–3)] was observed; 40% (p = 0.04) improvement was seen for the TSS [V1: 5.0 (IQR: 3–9), V5: 3.0 (IQR: 2–5.5)]. Analysis of temporal evolution of all symptom scores, and the personal well-being revealed sustained, clinically meaningful improvement at V5 compared to V1. No relevant lung function parameter differences were observed.ConclusionsSustained long-term reduction of TNSS (primary endpoint) and sustained long-term improvement of secondary endpoints (temporal evolution of all symptom scores and well-being) were demonstrated 7–8 months after cessation of holoBLG supplementation, indicative of a long-lasting nature of immune resilience induced by holoBLG.Trial registrationThe study was registered at clinicaltrials.gov (NCT04872868).

U2 - 10.1007/s40629-021-00197-z

DO - 10.1007/s40629-021-00197-z

M3 - SCORING: Journal article

VL - 31

SP - 161

EP - 171

JO - Allergo J Int

JF - Allergo J Int

SN - 2197-0378

ER -